Mendes Filho Daniel, Ribeiro Patrícia D C, Oliveira Lucas F, de Paula Diógenes R M, Capuano Vanessa, de Assunção Thaís S F, da Silva Valdo J D
Departments of Physiology, Biological and Natural Sciences Institute.
Nanocell Institute, Divinópolis, MG.
Neurologist. 2018 Jul;23(4):141-147. doi: 10.1097/NRL.0000000000000188.
Parkinson disease (PD) is a neurodegenerative disorder affecting the basal nuclei, causing motor and cognitive disorders. Bearing in mind that standard treatments are ineffective in delaying the disease progression, alternative treatments capable of eliminating symptoms and reversing the clinical condition have been sought. Possible alternative treatments include cell therapy, especially with the use of mesenchymal stem cells (MSC).
MSC are adult stem cells which have demonstrated remarkable therapeutic power in parkinsonian animals due to their differentiation competence, migratory capacity and the production of bioactive molecules. This review aims to analyze the main studies involving MSC and PD in more than a decade of studies, addressing their different methodologies and common characteristics, as well as suggesting perspectives on the application of MSC in PD.
The results of MSC therapy in animal models and some clinical trials suggest that such cellular therapy may slow the progression of PD and promote neuroregeneration. However, further research is needed to address the limitations of an eventual clinical application.
帕金森病(PD)是一种影响基底核的神经退行性疾病,会导致运动和认知障碍。鉴于标准治疗方法在延缓疾病进展方面无效,人们一直在寻找能够消除症状并逆转临床状况的替代治疗方法。可能的替代治疗方法包括细胞疗法,尤其是使用间充质干细胞(MSC)。
MSC是成体干细胞,由于其分化能力、迁移能力和生物活性分子的产生,已在帕金森病动物模型中显示出显著的治疗能力。本综述旨在分析十多年来涉及MSC和PD的主要研究,探讨其不同方法和共同特征,并提出MSC在PD中应用的前景。
MSC治疗在动物模型和一些临床试验中的结果表明,这种细胞疗法可能会减缓PD的进展并促进神经再生。然而,需要进一步研究以解决最终临床应用中的局限性。